SynthesisJournal of the American Heart Association2024
2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome.
Synthesis in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The effect of lifestyle interventions in women with polyendocrine metabolic ovarian syndrome: A systematic review and meta-analysis.PLoS medicine · 2026Pooled it
- Dose-response of acupuncture on ovulation rates in polycystic ovary syndrome: a meta-analysis and exploratory dose-response analysis.Frontiers in endocrinology · 2025Pooled it
- Beyond a Name Change: Polyendocrine Metabolic Ovarian Syndrome and a New Era of Opportunity for Research, Care, and Advocacy.International journal of endocrinology and metabolism · 2026Article
- From Gene Function to Precision Intervention: CRISPR/Cas9 and Stem Cell-Based Strategies as Emerging Disease-Modifying Approaches in PMOS.Stem cell reviews and reports · 2026Review
- Article
- Systems genetics approaches model the heritable architecture of polyendocrine metabolic ovarian syndrome.The Journal of clinical investigation · 2026Article
- Phenotype-Specific Differences in Insulin Resistance and Androgenic Profiles in Polycystic Ovary Syndrome: A Prospective Observational Study.Journal of clinical medicine · 2026Article
- Defining metabolic heterogeneity in polyendocrine metabolic ovarian syndrome based on the MTHFR C677T polymorphism: the potential pathway role of homocysteine.Journal of ovarian research · 2026Article
- Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.Diabetes, obesity & metabolism · 2026Article
- A Cross-Sectional Exploratory Study of Endothelial Biomarkers in Non-Obese Women with and Without Polyendocrine Metabolic Ovarian Syndrome.International journal of molecular sciences · 2026Article
- Obesity, Insulin Resistance, and Infertility in Women with Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study at a Tertiary Referral Medical Center in Qatar.Healthcare (Basel, Switzerland) · 2026Article
- Sex differences in cardiovascular‑kidney‑metabolic syndrome: From pathogenesis to treatment response (Review).International journal of molecular medicine · 2026Review
- Urinary Albumin-to-Creatinine Ratio Across Phenotypes of Polycystic Ovary Syndrome: A Phenotype-Based Evaluation.Metabolites · 2026Article
- Ketogenic diet as a therapeutic intervention for biochemical hyperandrogenism in PCOS women with obesity or overweight: a meta-analytic study.Journal of endocrinological investigation · 2026Review
- Modifiable cardiovascular risk factors in people with polycystic ovarian syndrome (PCOS): Findings from the endocrine and mental health study.American journal of preventive cardiology · 2026Article
- Cardiovascular-Kidney-Metabolic Syndrome: Development of anJMIR diabetes · 2026Article
- Challenges and knowledge gaps in sex differences in cardio-kidney-metabolic syndrome across the lifespan.Biology of sex differences · 2026Review
- Bridging the Practice Gap: Polycystic Ovary Syndrome as an Under-Recognised Risk State for Ischaemic Stroke and Cardiovascular Disease.Journal of clinical medicine · 2026Review
- Cerebrovascular Function in Women With Polycystic Ovary Syndrome: A Pilot Multi-Parameter Magnetic Resonance Imaging Study.Clinical endocrinology · 2026Article
- Testosterone Replacement Therapy in Women Is Associated with Improved Symptom Burden and Favorable Biomarker Changes: A Retrospective Observational Study.Journal of personalized medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is the most prevalent female endocrinopathy. Although increased cardiovascular risk factors are well established for the syndrome, PCOS remains overlooked within the realm of cardiology. We conducted a systematic review and meta-analysis on the risk of clinical cardiovascular disease (CVD) events in women with PCOS to inform the 2023 International Evidence-Based PCOS Guideline. METHODS AND
resultsA systematic review and meta-analysis was conducted comparing the risk of clinical CVD events in women with and without PCOS. Medline (Ovid), PsycInfo (Ovid), EMBASE, All EBM (Ovid), and CINAHL were searched from January 1, 2017, until March 1, 2023, to update the 2018 PCOS Guideline. Pooled odds ratios (ORs), incidence rate ratios (IRRs), and hazard ratios (HRs) were calculated. Twenty studies involving 1.06 million women (369 317 with PCOS and 692 963 without PCOS) were included. PCOS was associated with higher risk of composite CVD (OR, 1.68 [95% CI, 1.26-2.23]; I
conclusionsThis review provides evidence and highlights the importance of recognizing PCOS as a significant risk factor for CVD morbidity. The 2023 International Evidence-Based PCOS Guideline now recommends awareness of increased CVD risk and comprehensive risk assessment in PCOS to help mitigate the burden of CVD in this common and high-risk condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.